RWJBarnabas Health and Rutgers Health to Unveil Pioneering Cardiovascular Research at the American College of Cardiology's Annual Scientific Session & Expo
Research will highlight the latest advancements in cardiovascular care through 55 abstract presentations
WEST ORANGE, N.J., March 28, 2025 /PRNewswire/ -- Physician-scientists from RWJBarnabas Health and Rutgers Health will showcase a comprehensive collection of innovative cardiovascular research at this year's American College of Cardiology's Annual Scientific Session & Expo (ACC.25), taking place in Chicago, IL from March 29-31, 2025. A total of 55 abstracts will be presented, featuring clinical data and analyses that advance the understanding, treatment, and prevention of cardiovascular disease.
Research presented at the conference was conducted by residents and faculty in the cardiovascular service at Community Medical Center, Cooperman Barnabas Medical Center, Jersey City Medical Center, Newark Beth Israel Medical Center and Robert Wood Johnson University Hospital. RWJBarnabas Health cardiac centers of excellence are nationally recognized for patient care and superior outcomes, including being named as one of Becker's top 100 Great Heart Programs in the country and recognized by American College of Cardiology as a Proven Quality Program. Rutgers Health faculty presenting at the conference represents the Division of Cardiology and the Division of Cardiothoracic Surgery at Rutgers New Jersey Medical School, and the Division of Cardiovascular Diseases and Hypertension and the Division of Cardiothoracic Surgery at Robert Wood Johnson Medical School.
'We continue to drive advancements in cardiovascular care and enhance patient outcomes through transformative research and clinical excellence,' said Conor Barrett, MD, MBA, Senior Vice President and Chief Clinical Officer of RWJBarnabas Health Heart and Vascular Services. 'The data we are presenting at ACC.25 underscores our ongoing commitment to innovation in the prevention, diagnosis, and treatment of heart and vascular diseases. By leveraging cutting-edge science and fostering collaboration with leading experts, we are developing strategies that not only reduce cardiovascular risk but also improve the overall quality of life for patients in our communities.'
RWJBarnabas Health and Rutgers Health remain at the forefront of cardiovascular innovation. Their participation at ACC.25 reinforces their ongoing commitment to advancing research, improving patient outcomes, and shaping the future of heart and vascular care.
Highlights of the accepted abstracts include the following presentations:
Research exploring the use of machine learning models based on cardiac ultrasound radiomics (ultrasomics) to identify myocardial infarction with high accuracy. It compares traditional handcrafted ultrasound features with deep learning-based 3D convolutional neural networks, demonstrating that ultrasomics could provide the association with CMR-driven infarct localization and myocardial tissue characterization in acute myocardial infarction patients.
Highlights from a Fragility Index Analysis of the ARIES-HM3 trial, which evaluated the robustness of findings supporting an aspirin-free regimen in HeartMate III LVAD patients. The analysis confirms that the composite primary outcome (survival free of a major nonsurgical hemocompatibility-related adverse events, including stroke, pump thrombosis, major bleeding, or arterial thrombosis) remains robust with an FI of 24, driven primarily by a reduction in bleeding events, reinforcing the trial's potential practice-changing impact.
Findings from the FINEARTS-HF trial which demonstrated efficacy of finerenone in the reduction of a composite endpoint of cardiovascular death and heart failure events in patients with left ventricular ejection fraction (LVEF) ≥40%. This fragility index analysis confirms that these findings are remarkably robust, with a Fragility Index (FI) of 112, primarily driven by a significant reduction in heart failure hospitalizations (F1 of 112), making it more robust than most practice-changing trials in the cardiology field.
Immune checkpoint inhibitors (ICIs) are widely used in cancer treatment but can cause rare, life-threatening myocarditis. Our findings highlight that timely recognition and management of ICI-induced myocarditis are crucial to preventing severe cardiac complications.
Hypertrophic obstructive cardiomyopathy (HOCM) is a complex, life-threatening disease with limited treatment options, however the approval of Mavacamten introduced a novel approach by directly targeting the disease's molecular pathology. Our findings suggest the need for further research to evaluate long-term side effects of Mavacamten.
The full list of presentations at this year's ACC.25 Annual Scientific Session & Expo can be found here.
About RWJBarnabas Health
RWJBarnabas Health is the largest, most comprehensive academic health care system in New Jersey, with a service area covering eight counties with five million people. The system includes twelve acute care hospitals – Clara Maass Medical Center in Belleville, Community Medical Center in Toms River, Cooperman Barnabas Medical Center in Livingston, Jersey City Medical Center in Jersey City, Monmouth Medical Center in Long Branch, Monmouth Medical Center Southern Campus in Lakewood, Newark Beth Israel Medical Center in Newark, Robert Wood Johnson University Hospital in New Brunswick, Robert Wood Johnson University Hospital Somerset in Somerville, Robert Wood Johnson University Hospital Hamilton in Hamilton, Robert Wood Johnson University Hospital Rahway in Rahway and Trinitas Regional Medical Center in Elizabeth, three acute care children's hospitals, Children's Specialized Hospital with a network of outpatient pediatric rehabilitation centers, a freestanding 100-bed behavioral health center, two trauma centers, a satellite emergency department, ambulatory care centers, geriatric centers, the state's largest behavioral health network, comprehensive home care and hospice programs, fitness and wellness centers, retail pharmacy services, affiliated medical groups, multi-site imaging centers and two accountable care organizations.
RWJBarnabas Health is among New Jersey's largest private employers – with more than 41,000 employees and 9,000 physicians– and routinely captures national awards for outstanding quality and safety. RWJBarnabas Health launched an affiliation with Rutgers University to create New Jersey's largest academic health care system. The collaboration aligns RWJBarnabas Health with Rutgers' education, research and clinical activities, including those at the Rutgers Cancer Institute of New Jersey - the state's only NCI-designated Comprehensive Cancer Center - and Rutgers University Behavioral Health Care.
For journalists – contact:
732.507.8307
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
MLB prospect analyst rips Boston College coaches for allowing pitcher to throw nearly 240 pitches during ACC tournament
A top MLB prospect analyst is blasting Boston College baseball coaches for allowing a pitcher to throw nearly 240 pitches in a week during the ACC tournament. Junior A.J. Colarusso threw 237 pitches, including 109 in six innings during the Eagles' elimination game 7-2 loss to Notre Dame last Friday. The 109-pitch outing came just two days after Colarusso went four innings and 72 pitches in BC's 12-8 win over Virginia. Advertisement 'Colarusso doesn't throw very hard — he sits 87-89, and it's not a high-effort delivery — but the issue with overuse is fatigue, and that affects everyone,' notes The Athletic's Keith Law. 'The usage blew past the MLB PitchSmart recommendations for a pitcher his age when working on two days of rest (maximum of 60 pitches), even though 'numerous studies have shown that … pitching too deep into games, violating pitch count recommendations, and acute spikes in workload significantly increase the risk of injury,' according to the PitchSmart site. They also recommend a maximum of 120 pitches in any game for any pitcher aged 19-22.' The ACC Baseball X account even celebrated Colarusso's performance on social media, posting: '109 pitches on the night. 237 pitches on the week. An incredible ACC Championship performance from No. 48.' 'It was an outstanding performance by Colarusso, but the coaches and the people running the conference are supposed to be the adults in the room here, and 181 pitches over four days is not something to cheer,' states Law. '(He'd thrown another 56 pitches the prior Thursday, hence the 237 pitches figure in their tweet.)' Advertisement Law called it incredibly irresponsible for college coaches to allow pitchers like Colarusso, who might not have a professional future, to risk a traumatic arm or shoulder injury that could affect them beyond baseball. The Athletic's senior baseball writer added that it's a 'terrible idea' for MLB to be 'farming out some of their player development to college programs.' 'College coaches can not be trusted,' Law said succinctly. With BC's loss in the ACC tournament, the Eagles will not advance to the NCAA Tournament.
Associated Press
2 days ago
- Associated Press
CannabisNewsWire is the Official NewsWire sponsor of CMB
AUSTIN, Texas, May 28, 2025 (GLOBE NEWSWIRE) -- CannabisNewsWire (CNW), a leading communications platform for the cannabis industry and part of the InvestorBrandNetwork (IBN), is thrilled to announce its engagement as the official newswire for Cannabis Means Business (CMB) – Conference and Expo event. The event shall take place on June 4-5, 2025, at the Javits Convention Center in New York City. In addition, InvestorBrandNetwork is the Official Media Sponsor of CMB. Now in its 11th year, CMB (formerly CWCBExpo) is renowned for providing an unparalleled platform for networking, education, and business development. Featuring industry-leading speakers, product showcases, workshops and trainings and a state-of-the-art exhibition space, the event will offer world-class educational experiences and opportunities for high-powered networking. The conference's attendees will include seasoned investors and venture capitalists; cannabis entrepreneurs and business owners; dispensary and retail operators; manufacturers, cultivators, and suppliers; legal, compliance, and regulatory professionals, as well as industry influencers and advocates. In its capacity as the media sponsor for the event, IBN will harness its comprehensive corporate communications solutions to enhance the conference's visibility through an impressive array of strategic tools and influential digital channels. This approach aims to expand the reach of invited speakers, event sponsors and the conference itself, leveraging the power of multi-brand social media technologies and IBN's expansive syndication network. Furthermore, IBN will provide a complimentary syndicated article for each presenting company to amplify their reach. With a coverage network extending to 5,000+ syndication partners and a diverse array of online channels, IBN will be further extending the conference's digital presence. Christine Ianuzzi, CEO of CMB, commented, 'Now in our 11th year, and having rebranded as CMB, we are pleased to continue our collaboration with IBN for this landmark event in New York City. As the market leader in corporate communications, IBN has a strong track record of amplifying event outreach into both new and established markets and providing seamless and high-quality media coverage at our conferences. This is a must-attend event for both parties that are newly interested in this space and seasoned participants. We look forward to meeting everyone at the event.' Randy Clark, Director of Global Operations for IBN, added, 'CMB (formerly CWCBExpo) has honed a strong reputation for excellence in the production of high-value, industry-flagship events for traders, investors and other market participants across the spectrum of cannabis related services and products. To support the conference's outreach and messaging, IBN shall deploy the latest in social media tools and public relations strategies. Our team is looking forward to working closely with the highly energetic CMB team to optimize visibility among national and international audiences.' For registration, please visit the following link: About IBN IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients. Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: Corporate Communications IBN Austin, Texas 512.354.7000 Office [email protected]
New York Post
17-05-2025
- New York Post
‘Hollywood Medium' Tyler Henry, 29, reveals he had brain tumor — 4 symptoms to look out for
'Hollywood Medium' Tyler Henry is 'on the mend' after undergoing surgery to remove part of a rare tumor growing near the center of his brain. 'Great prognosis, incredible staff, and I feel so thankful to be surrounded by my family,' the 29-year-old clairvoyant — who's read for stars like the Kardashians, Megan Fox, and Chad Michael Murray — wrote in a May 14 Instagram post. The tumor, known as a colloid cyst, is noncancerous but potentially dangerous if left untreated. Here's what you need to know about the condition, including the signs that one might be quietly lurking in your brain. Advertisement 4 'Hollywood Medium' Tyler Henry plans to return to his famous readings once fully recovered. Getty Images for the Critics Choice Real TV Awards What are colloid cysts? Colloid cysts are rare, benign and slow-growing brain lesions, making up an estimated 0.5% to 1% of all primary brain tumors, according to Barrow Neurological Institute. While doctors don't know exactly what causes them, researchers believe these fluid-filled sacs begin forming during fetal development. Advertisement Colloid cysts are typically found deep in the brain's third ventricle — a narrow passage that helps circulate cerebrospinal fluid (CSF), the clear liquid that cushions and protects your brain and spinal cord. Most sit silently for years, causing no issues. But if a cyst grows large enough, it can block the flow of CSF, leading to a dangerous buildup in the brain known as hydrocephalus. 4 Colloid cysts can lead to a buildup of cerebrospinal fluid, increasing pressure on the brain. sudok1 – Advertisement That fluid pressure can damage brain tissues and trigger serious neurological problems. In severe cases, it can become life-threatening — and even lead to sudden death if left untreated. What are the symptoms of colloid cysts? Colloid cysts are often asymptomatic, and many people don't know they have one until it shows up unexpectedly on a brain scan for something else, according to RWJ Barnabas Health. When signs do appear, it's typically because the cyst has grown large enough to interfere with normal brain function, usually occurring after the age of 30. Symptoms can vary depending on where the lesion is located in the brain, but red flags often include headaches, memory problems, behavioral changes and brief losses of consciousness, which can escalate to coma in some cases. Advertisement 4 Symptoms depend on which part of the brain the cyst is growing in. Studio Romantic – If the cyst causes hydrocephalus, additional symptoms may surface, such as confusion, double vision, fatigue and difficulty walking. How do you treat colloid cysts? Doctors usually keep a close eye on small, symptom-free cysts with annual scans. But once they cause problems, surgery becomes the main option, according to Columbia Neurosurgery. The traditional method is a craniotomy, where surgeons open a section of the skull to access the cyst. However, in a growing number of cases, a less invasive endoscopic craniotomy is performed, in which doctors use a small tube with a camera and surgical tools to remove the cyst through a tiny incision. 4 This marked the second time the Hollywood medium had to receive brain surgery. Tyler Henry/Instagram Complete removal of a colloid cyst usually means a cure, but in some cases — like Henry's — only partial removal is possible due to factors such as the tumor's size and location. Advertisement 'For those curious,' the 'Life After Death' star explained to his 1.2 million followers, 'I had a colloid tumor near the center of my brain and thankfully most of it has been removed! (The tumor, not my brain… that is.)' Partial removal significantly raises the risk of the cyst returning. Patients in these cases are typically monitored closely with regular brain scans to catch any signs of regrowth early. If the cyst is too risky to remove surgically, doctors may opt to insert a shunt to drain excess CSF and reduce pressure on the brain. A shunt may also be used if hydrocephalus continues even after the cyst has been removed.
